| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.05. | Franklin Metaverse UCITS ETF: Namensänderung | 24 | Dow Jones News | Sie erhalten diese Mitteilung, da Sie Anteile am Franklin Metaverse UCITS ETF (der "Teilfonds") besitzen, einem Teilfonds des Franklin Templeton ICAV (das "ICAV").
Dieses Dokument ist wichtig und... ► Artikel lesen | |
| 23.05. | Scandion Oncology A/S: Scandion Oncology Announces The Final Terms Of The Rights Issue | 123 | GlobeNewswire (Europe) | On 19 April 2024, the board of directors of Scandion Oncology ("Scandion" or the "Company") resolved on the intention, subject to authorizations by the annual general meeting of the Company, to carry... ► Artikel lesen | |
| 23.05. | Nordrest Holding AB: Nordrest's offering was substantially oversubscribed - trading in the share on Nasdaq First North Growth Market commences today | 241 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, DISTRIBUTED OR PUBLISHES, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW ZEALAND, RUSSIA... ► Artikel lesen | |
| 23.05. | X-FAB and Soitec team to offer SmartSiC at Lubbock plant in Texas | 7 | Semiconductor Today | ||
| 23.05. | Navitas highlights power semis for AI, EV, industrial, solar and energy storage at PCIM | 7 | Semiconductor Today | ||
| 23.05. | Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer? | 30 | Business Wire | BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety... ► Artikel lesen | |
| 23.05. | ACCIONA, S.A.: Q1 2024 Trading Statement (January - March) | 102 | GlobeNewswire (Europe) | EXECUTIVE SUMMARY
ACCIONA has begun 2024 progressing well towards its objective of installing 1.7 GW of new renewable energy capacity for the second year in a row, and achieving strong performance... ► Artikel lesen | |
| 23.05. | Bowhead Specialty Announces Pricing of Upsized Initial Public Offering | 62 | Business Wire | NEW YORK--(BUSINESS WIRE)--Bowhead Specialty Holdings Inc. (the "Company", "Bowhead Specialty", "we" or "our") announced today the pricing of its upsized initial public offering of 7,529,412 shares... ► Artikel lesen | |
| 23.05. | Millicom International Cellular S.A.: Millicom (Tigo) comments on shareholder communication | 253 | GlobeNewswire (Europe) | Millicom (Tigo) comments on shareholder communication Luxembourg, May 23, 2024 - The Board of Directors of Millicom International Cellular S.A. ("Millicom") confirms that it received today a non-binding... ► Artikel lesen | |
| 23.05. | Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide | 155 | GlobeNewswire (Europe) | Company announcement - No. 27 / 2024 Zealand Pharma announces topline results from the mechanistic investigator-led DREAM trial with low doses of GLP-1/GLP-2 receptor dual agonist dapiglutide Mean... ► Artikel lesen | |
| 23.05. | Pepco Group N.V.: Interim results for six months ended 31 March 2024 | 76 | GlobeNewswire (Europe) | Strong H1 profit growth with tangible strategic progress
Pepco Group, the fast-growing pan-European variety discount retailer, today reports interim results for the six-month period ended 31 March... ► Artikel lesen | |
| 23.05. | Coherus BioSciences, Inc.: Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 124 | GlobeNewswire (Europe) | CHS-114 shown to have an acceptable safety profile with no dose-limiting toxicities (DLTs) in heavily pretreated patients with solid tumors Selective depletion of peripheral CCR8+ regulatory T cells... ► Artikel lesen | |
| 23.05. | Premier Health of America Inc.: Premier Health Reports 2024 Second Quarter Results | 330 | GlobeNewswire (Europe) | MONTRÉAL, May 23, 2024 (GLOBE NEWSWIRE) -- Premier Health of America Inc. (TSXV: PHA) (the "Corporation"), a leading Canadian Healthtech company, announces it has filed its Unaudited Quarterly Consolidated... ► Artikel lesen | |
| 23.05. | Elicio Therapeutics, Inc.: Elicio Therapeutics Announces Preliminary Data from the Ongoing AMPLIFY-7P Phase 1a Study of ELI-002 7P in Patients with mKRAS-driven Solid Tumors at the 2024 ASCO Annual Meeting | 78 | GlobeNewswire (Europe) | ELI-002 7P administered as a monotherapy was well tolerated and able to generate a ~100x mKRAS-specific expanded T cell response relative to baseline levelsELI-002 7P generated an mKRAS-specific T... ► Artikel lesen | |
| 23.05. | Fresh2 Group Ltd. Announces Receipt of a Delinquency Compliance Alert Notice from Nasdaq | 80 | GlobeNewswire (Europe) | New York, NY, May 23, 2024 (GLOBE NEWSWIRE) -- Fresh2 Group Ltd. (NASDAQ: FRES) ("Fresh2" or the "Company"), a B2B e-commerce and supply chain management company within the restaurant and food industry... ► Artikel lesen | |
| 23.05. | Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 | 195 | GlobeNewswire (Europe) | - Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast... ► Artikel lesen | |
| 23.05. | Affimed N.V.: Affimed Announces Positive Early Efficacy and Progression Free Survival Results of AFM24-102 Study in EGFR Wild-Type Non-Small Cell Lung Cancer at the Annual Meeting of the American Society of Clinical Oncology 2024 | 123 | GlobeNewswire (Europe) | In 15 response-evaluable patients with metastatic EGFR wild-type NSCLC, who were pretreated with platinum doublet chemotherapy and checkpoint inhibitors, the combination of AFM24 and atezolizumab... ► Artikel lesen | |
| 23.05. | Elcora Advanced Materials Corp.: Elcora Announces Share Consolidation | 115 | GlobeNewswire (Europe) | HALIFAX, Nova Scotia, May 23, 2024 (GLOBE NEWSWIRE) -- ELCORA ADVANCED MATERIALS CORP. (TSX.V:ERA | Frankfurt:ELM | OTCQB - ECORF), (the "Company" or "Elcora"), a leading battery metals exploration... ► Artikel lesen | |
| 23.05. | NKGen Biotech, Inc.: NKGen Biotech Publishes Phase 1 Interim Analysis Results of SNK02 Allogeneic NK Cell Therapy in Advanced Solid Tumors at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting | 110 | GlobeNewswire (Europe) | SNK02 has the potential to be a first-in-class cryopreserved allogeneic NK cell therapy for solid tumors that does not require lymphodepletion before administration, which may lead to better overall... ► Artikel lesen | |
| 23.05. | Regeneron Pharmaceuticals, Inc.: Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo (cemiplimab) to be Reported at ASCO | 80 | GlobeNewswire (Europe) | Oral presentation to highlight activity of REGN7075 in combination with Libtayo from dose-escalation portion of trial in patients with microsatellite stable colorectal cancer, which has historically... ► Artikel lesen |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 3.968 |
| EVOTEC | 3.343 |
| TUI | 2.191 |
| GAMESTOP | 2.057 |
| NEL | 1.952 |
| BAYER | 1.638 |
| BYD | 1.519 |
| RHEINMETALL | 1.345 |
| SMA SOLAR | 1.308 |
| CAVENDISH HYDROGEN | 1.175 |
| DEUTSCHE LUFTHANSA | 1.165 |
| AIXTRON SE | 986 |
| TESLA | 974 |
| SUPER MICRO COMPUTER | 897 |
| VOLKSWAGEN | 797 |
| THYSSENKRUPP | 720 |
| PALANTIR TECHNOLOGIES | 696 |
| DEFI TECHNOLOGIES | 686 |
| APPLE | 654 |
| BASF | 646 |
| BIONTECH | 631 |
| CARL ZEISS MEDITEC | 604 |
| HEIDELBERGER DRUCK | 595 |
| RENK GROUP | 590 |
| DEUTSCHE BANK | 589 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
